Asian Pacific Journal of Cancer Prevention

  • 제16권14호
  • /
  • Pages.5945-5950
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Incidence, Risk Factors, and Outcomes of Febrile Neutropenia in Thai Hematologic Malignancy Patients Receiving Chemotherapy: A 6-year Retrospective Cohort Study

  • 발행 : 2015.09.02
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A 6-year retrospective cohort study was conducted among Thai hematologic malignancy (HM) patients receiving intensive chemotherapy. Of the 145 eligible patients receiving 893 chemotherapy sessions, 46.9% were female, median age was 52 years, and the most common HM diagnosis was diffuse large B-cell lymphoma (46.2%). Febrile neutropenia (FN) occurred in 14.9% of chemotherapy sessions with an incidence of 24.8 per 1,000 chemotherapy cycles per year. Independent factors associated with FN were receiving the first chemotherapy cycle [adjusted hazard ratio (aHR) 4.1], having hemoglobin ${\leq}100g/L$ (aHR 3.7) and platelet ${\leq}140,000/{\mu}L$ (aHR 2.7) on chemotherapy day and receiving acute myeloid leukemia regimens (aHR 20.8). Granulocyte colony stimulating factor was significantly associated with reduced rate of FN when given in those receiving CHOP regimen. With the median follow-up time of 16 months, the overall survival time was significantly longer in patients without FN than those with FN (61.7 vs. 20.8 months; p<0.001).

키워드

참고문헌

  1. Chan A, Chen C, Chiang J, et al (2012). Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer, 1525-32.
  2. Chayakulkeeree M, Thamlikitkul V (2003). Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever. J Med Assoc Thai, 86, 212-23.
  3. Chindaprasirt J, Wanitpongpun C, Limpawattana P, et al (2013). Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev, 14, 1115-9. https://doi.org/10.7314/APJCP.2013.14.2.1115
  4. Choi YW, Jeong SH, Ahn MS, et al (2014). Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab- CHOP. J Korean Med Sci, 1493-500.
  5. Crawford J, Armitage J, Balducci L, et al (2013). Myeloid growth factors. J Natl Compr Canc Netw, 11, 1266-90.
  6. Crawford J, Dale DC, Kuderer NM, et al (2008). Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw, 6, 109-18.
  7. Freifeld AG, Bow EJ, Sepkowitz KA, et al (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis, 52, 56-93. https://doi.org/10.1093/cid/cir073
  8. Hassan BAR, Yusoff ZBM, Ohtman SB (2009). Neutropenia onset, severity, and their association with demographic data. Asian J Pharm Clin Res, 2, 51-3.
  9. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al (2000). A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma, 37, 351-60.
  10. Klastersky J (2004). Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis, 39, 32-7. https://doi.org/10.1086/383050
  11. Klastersky J, Paesmans M, Rubenstein EB, et al (2000). The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol, 18, 3038-51.
  12. Kuderer NM, Dale DC, Crawford J, et al (2007). Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol, 25, 3158-67. https://doi.org/10.1200/JCO.2006.08.8823
  13. Lal A, Bhurgri Y, Rizvi N, et al (2008). Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. Asian Pac J Cancer Prev, 9, 303-8.
  14. Leelayuthachai T, Kanitsap N (2010). Febrile neutropenia in post-chemotherapeutic patients in medicine department, thammasat university hospital. J Hematol Transfus Med, 20, 197-203.
  15. Lyman GH, Kuderer NM, Crawford J, et al (2011). Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer, 117, 1917-27. https://doi.org/10.1002/cncr.25691
  16. Lyman GH, Michels SL, Reynolds MW, et al (2010). Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer, 116, 5555-63. https://doi.org/10.1002/cncr.25332
  17. Osmani AH, Ansari TZ, Masood N, et al (2012). Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital. Asian Pac J Cancer Prev, 13, 2523-6. https://doi.org/10.7314/APJCP.2012.13.6.2523
  18. Pettengell R, Bosly A, Szucs TD, et al (2009). Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol, 144, 677-85. https://doi.org/10.1111/j.1365-2141.2008.07514.x
  19. Roongpoovapatr P, Suankratay C (2010). Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital. J Med Assoc Thai, 93, 776-83.
  20. Salar A, Haioun C, Rossi FG, et al (2012). The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res, 36, 548-53. https://doi.org/10.1016/j.leukres.2012.02.002
  21. Wolff D, Culakova E, Poniewierski MS, et al (2005). Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol, 3, 24-5.